Clinical Trials Logo

Preterm Labor Without Delivery clinical trials

View clinical trials related to Preterm Labor Without Delivery.

Filter by:
  • None
  • Page 1

NCT ID: NCT05520021 Recruiting - Pregnancy Preterm Clinical Trials

The Treatment of Magnesium Sulfate and Nifedipine in Preterm Labor Threat

MgSO4
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

Comparison of the effects of Nifedipine and MgSO4 therapies on maternal and fetal blood flow.

NCT ID: NCT04644354 Not yet recruiting - Preterm Birth Clinical Trials

The Efficacy of Nifedipine in the Management of Preterm Labor

BOG/TH/PTL
Start date: December 15, 2020
Phase:
Study type: Observational

Preterm labor is one of the problems of obstetrics, and is one of the leading cause of neonatal morbidity and mortality. The incidence of preterm birth is around 7 to 9 %. The preterm baby is prone to respiratory, renal, neurologic and gastrointestinal problems. The correct diagnosis should be followed by the early administration of the most effective tocolytic agent with least side effects for both mother and fetus. Nifedipine, a calcium channel blocker, has gained a world-wide popularity recently since it has the least side-effects on both mother and fetus. In the present study, we aimed to evaluate the success rate of tocolytic agent 'nifedipine' on the spontaneous preterm labor of singeton pregnant women with intact amnionic membrane.

NCT ID: NCT03298191 Recruiting - Clinical trials for Preterm Labor Without Delivery

Tocolysis in Prevention of Preterm Labor

Start date: October 25, 2017
Phase: Phase 4
Study type: Interventional

Preterm birth is defined as birth before 37 completed weeks of gestation .it occurs in 11.1%of birth globally affecting an estimated 14.9 million babies every year . It is generally accepted that approximately 65%-70%of preterm births are spontaneous,40%-45% of them due to spontaneous preterm labor and 25%-30%following preterm rupture of membranes.preterm birth represents the single largest cause of morbidity and mortality for newborn and is estimated for 29%of deaths in the first four weeks of life and also is estimated for of major cause of morbidity for pregnant women . Tocolytic agents include a wide range of drugs that can slow or suppress uterine contractions . Tocolytic are considered advantages in spontaneous preterm labor to : (a) allow time for the fetus to mature ,potentially avoiding deleterious effects of pre-maturity . (b)allow time for antenatal corticosteroids to be administered and have clinical effect. (c) allow time for intrauterine transfer to higher-care center where neonatal intensive care facilities are available . the ideal Tocolytic agent should be effective , easy to administer , without significant material ,fetal or neonatal side effects and permit time for antenatal corticosteroids to be administered and take effect . a variety of Tocolytic treatments have been used to inhibit uterine activity in women in spontaneous preterm labor , including betamimetics , calcium channel blockers , magnesium sulfate , prostaglandin inhibitors and oxytocin receptor antagonists however there is considerable global variation in types , doses and regimens of tocolytic agents uses to manage preterm labor . A comparison study between Ritodrine, magnesium sulfate and Nifedipine in terms of effect and morbidity will be conducted.